Robert Luedtke - Publications

Affiliations: 
Pharmacology and Neuroscience University of North Texas Health Science Center at Fort Worth 
Area:
Neuroscience Biology

93 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Chen PJ, Taylor M, Griffin SA, Amani A, Hayatshahi H, Korzekwa K, Ye M, Mach RH, Liu J, Luedtke RR, Gordon JC, Blass BE. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D receptor ligands. Bioorganic & Medicinal Chemistry Letters. PMID 31387791 DOI: 10.1016/j.bmcl.2019.07.020  0.44
2019 Reilly SW, Riad AA, Hsieh CJ, Sahlholm K, Jacome DA, Griffin S, Taylor M, Weng CC, Xu K, Kirschner N, Luedtke RR, Parry C, Malhotra S, Karanicolas J, Mach RH. Leveraging a Low Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity Across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs). Journal of Medicinal Chemistry. PMID 31021617 DOI: 10.1021/acs.jmedchem.9b00412  0.44
2019 Powell GL, Bonadonna JP, Vannan A, Xu K, Mach RH, Luedtke RR, Neisewander JL. Retraction notice to "Dopamine Ds3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors" [Pharmacology, Biochemistry and Behavior 171 (2018) 46-53]. Pharmacology, Biochemistry, and Behavior. 176: 111. PMID 30616777 DOI: 10.1016/j.pbb.2018.12.011  0.44
2018 Powell GL, Bonadonna JP, Vannan A, Mach RH, Luedtke RR, Neisewander JL. Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacology, Biochemistry, and Behavior. PMID 30308214 DOI: 10.1016/j.pbb.2018.10.002  0.44
2018 Hayatshahi HS, Xu K, Griffin SA, Taylor M, Mach RH, Liu J, Luedtke RR. Analogs of Arylamide Phenylpiperazine Ligands to Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity. Acs Chemical Neuroscience. PMID 30010318 DOI: 10.1021/acschemneuro.8b00142  0.44
2018 Powell GL, Bonadonna JP, Vannan A, Xu K, Mach RH, Luedtke RR, Neisewander JL. Dopamine Ds3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacology, Biochemistry, and Behavior. PMID 29807065 DOI: 10.1016/j.pbb.2018.05.015  0.44
2017 Reilly SW, Griffin S, Taylor M, Sahlholm K, Weng CC, Xu K, Jacome DA, Luedtke RR, Mach RH. Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores. Journal of Medicinal Chemistry. PMID 29125762 DOI: 10.1021/acs.jmedchem.7b01248  0.44
2017 Mach RH, Luedtke RR. Challenges in the Development of Dopamine D2- and D3-selective Radiotracers for PET Imaging Studies. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 28857231 DOI: 10.1002/jlcr.3558  0.44
2016 Rangel-Barajas C, Estrada-Sánchez AM, Barton SJ, Luedtke RR, Rebec GV. Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine. Neuropharmacology. PMID 27816502 DOI: 10.1016/j.neuropharm.2016.11.001  0.44
2016 Malik M, Rangel-Barajas C, Mach RH, Luedtke RR. The Effect of the Sigma-1 Receptor Selective Compound LS-1-137 on the DOI-Induced Head Twitch Response in Mice. Pharmacology, Biochemistry, and Behavior. PMID 27397487 DOI: 10.1016/j.pbb.2016.07.001  0.44
2015 Luedtke RR, Rangel-Barajas C, Malik M, Reichert DE, Mach RH. Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics. Current Pharmaceutical Design. 21: 3700-24. PMID 26205291  0.44
2015 Rangel-Barajas C, Malik M, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds. Neuropharmacology. 93: 179-90. PMID 25698528 DOI: 10.1016/j.neuropharm.2014.10.030  0.44
2015 Malik M, Rangel-Barajas C, Sumien N, Su C, Singh M, Chen Z, Huang RQ, Meunier J, Maurice T, Mach RH, Luedtke RR. The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. British Journal of Pharmacology. 172: 2519-31. PMID 25573298 DOI: 10.1111/bph.13076  0.44
2015 Peng X, Wang Q, Mishra Y, Xu J, Reichert DE, Malik M, Taylor M, Luedtke RR, Mach RH. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorganic & Medicinal Chemistry Letters. 25: 519-23. PMID 25556097 DOI: 10.1016/j.bmcl.2014.12.023  0.44
2014 Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Journal of Medicinal Chemistry. 57: 7042-60. PMID 25126833 DOI: 10.1021/jm500801r  0.4
2014 Rangel-Barajas C, Malik M, Taylor M, Neve KA, Mach RH, Luedtke RR. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. Journal of Neurochemistry. 131: 418-31. PMID 25041389 DOI: 10.1111/jnc.12825  0.44
2014 Rangel-Barajas C, Malik M, Vangveravong S, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds. Neuropharmacology. 83: 18-27. PMID 24680675 DOI: 10.1016/j.neuropharm.2014.03.003  0.44
2013 Tu Z, Li S, Li A, Taylor M, Ho D, Malik M, Luedtke RR, Mach RH. Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands. Medchemcomm. 4: 1283-1289. PMID 24156012 DOI: 10.1039/C3MD00098B  0.44
2013 Cheung TH, Loriaux AL, Weber SM, Chandler KN, Lenz JD, Schaan RF, Mach RH, Luedtke RR, Neisewander JL. Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55. The Journal of Pharmacology and Experimental Therapeutics. 347: 410-23. PMID 24018640 DOI: 10.1124/jpet.112.202911  0.44
2013 Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR. The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition. Pharmacology. 92: 84-9. PMID 23942137 DOI: 10.1159/000351971  0.44
2013 Nolan BC, Liu S, Hammerslag LR, Cheung TH, Lenz J, Mach RH, Luedtke RR, Neisewander JL. Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine. Synapse (New York, N.Y.). 67: 847-55. PMID 23766142 DOI: 10.1002/syn.21691  0.44
2013 Li A, Mishra Y, Malik M, Wang Q, Li S, Taylor M, Reichert DE, Luedtke RR, Mach RH. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. Bioorganic & Medicinal Chemistry. 21: 2988-98. PMID 23618707 DOI: 10.1016/j.bmc.2013.03.074  0.44
2013 Newman AH, Banala AK, Donthamsetti P, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L. Drug Design for Addiction - Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 181-182. DOI: 10.1016/B978-0-12-800044-1.00163-X  0.44
2012 Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangveravong S, Dillon GH, Huang RQ, Reichert DE, Mach RH. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. Acs Chemical Neuroscience. 3: 1050-62. PMID 23259040 DOI: 10.1021/cn300142q  0.44
2012 Cheung TH, Nolan BC, Hammerslag LR, Weber SM, Durbin JP, Peartree NA, Mach RH, Luedtke RR, Neisewander JL. Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats. Neuropharmacology. 63: 1346-59. PMID 22960444 DOI: 10.1016/j.neuropharm.2012.08.011  0.44
2012 Minton AZ, Phatak NR, Stankowska DL, He S, Ma HY, Mueller BH, Jiang M, Luedtke R, Yang S, Brownlee C, Krishnamoorthy RR. Endothelin B receptors contribute to retinal ganglion cell loss in a rat model of glaucoma. Plos One. 7: e43199. PMID 22916224 DOI: 10.1371/journal.pone.0043199  0.44
2012 Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, Levy B, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Journal of Medicinal Chemistry. 55: 6689-99. PMID 22632094 DOI: 10.1021/jm300482h  0.44
2012 Luedtke RR, Perez E, Yang SH, Liu R, Vangveravong S, Tu Z, Mach RH, Simpkins JW. Neuroprotective effects of high affinity Σ1 receptor selective compounds. Brain Research. 1441: 17-26. PMID 22285434 DOI: 10.1016/j.brainres.2011.12.047  0.44
2011 Wang W, Cui J, Lu X, Padakanti PK, Xu J, Parsons SM, Luedtke RR, Rath NP, Tu Z. Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors. Journal of Medicinal Chemistry. 54: 5362-72. PMID 21732626 DOI: 10.1021/jm200203f  0.44
2011 Tu Z, Li S, Xu J, Chu W, Jones LA, Luedtke RR, Mach RH. Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nuclear Medicine and Biology. 38: 725-39. PMID 21718948 DOI: 10.1016/j.nucmedbio.2011.01.002  0.44
2011 Vangveravong S, Zhang Z, Taylor M, Bearden M, Xu J, Cui J, Wang W, Luedtke RR, Mach RH. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound. Bioorganic & Medicinal Chemistry. 19: 3502-11. PMID 21536445 DOI: 10.1016/j.bmc.2011.04.021  0.44
2011 Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. Journal of Medicinal Chemistry. 54: 3581-94. PMID 21495689 DOI: 10.1021/jm200288r  0.44
2011 Tu Z, Li S, Cui J, Xu J, Taylor M, Ho D, Luedtke RR, Mach RH. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands. Journal of Medicinal Chemistry. 54: 1555-64. PMID 21348515 DOI: 10.1021/jm101323b  0.44
2011 Blaylock BL, Gould RW, Banala A, Grundt P, Luedtke RR, Newman AH, Nader MA. Influence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 1104-13. PMID 21289600 DOI: 10.1038/npp.2010.248  0.44
2011 Mach RH, Tu Z, Xu J, Li S, Jones LA, Taylor M, Luedtke RR, Derdeyn CP, Perlmutter JS, Mintun MA. Endogenous dopamine (DA) competes with the binding of a radiolabeled D3 receptor partial agonist in vivo: A positron emission tomography study Synapse. 65: 724-732. PMID 21132811 DOI: 10.1002/syn.20891  0.44
2011 Karimi M, Moerlein SM, Videen TO, Luedtke RR, Taylor M, Mach RH, Perlmutter JS. Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect? Movement Disorders. 26: 100-106. PMID 20960437 DOI: 10.1002/mds.23401  0.44
2011 Riddle LR, Kumar R, Griffin SA, Grundt P, Newman AH, Luedtke RR. Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats. Neuropharmacology. 60: 284-94. PMID 20850462 DOI: 10.1016/j.neuropharm.2010.09.011  0.44
2010 Wang Q, Mach RH, Luedtke RR, Reichert DE. Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. Journal of Chemical Information and Modeling. 50: 1970-85. PMID 20936866 DOI: 10.1021/ci1002747  0.44
2010 Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Molecular Pharmacology. 78: 925-34. PMID 20702763 DOI: 10.1124/mol.110.065755  0.44
2010 Vangveravong S, Taylor M, Xu J, Cui J, Calvin W, Babic S, Luedtke RR, Mach RH. Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorganic & Medicinal Chemistry. 18: 5291-300. PMID 20542439 DOI: 10.1016/j.bmc.2010.05.052  0.44
2010 Xu J, Hassanzadeh B, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)- butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate-putamen Synapse. 64: 449-459. PMID 20175227 DOI: 10.1002/syn.20748  0.44
2010 Taylor M, Grundt P, Griffin SA, Newman AH, Luedtke RR. Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Synapse (New York, N.Y.). 64: 251-66. PMID 19924694 DOI: 10.1002/syn.20725  0.44
2009 Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow NR. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacology, Biochemistry, and Behavior. 93: 141-7. PMID 19426754 DOI: 10.1016/j.pbb.2009.04.022  0.44
2009 Xu J, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH. [3H]4-(dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl]benzamide, a selective radioligand for dopamine D3 receptors. I. In vitro characterization Synapse. 63: 717-728. PMID 19425052 DOI: 10.1002/syn.20652  0.44
2009 Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR. Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats Neuropharmacology. 56: 956-969. PMID 19371586 DOI: 10.1016/j.neuropharm.2009.01.019  0.44
2009 Kumar R, Riddle L, Griffin SA, Grundt P, Newman AH, Luedtke RR. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology. 56: 944-55. PMID 19371585 DOI: 10.1016/j.neuropharm.2009.01.020  0.44
2009 Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. Journal of Medicinal Chemistry. 52: 2559-70. PMID 19331412 DOI: 10.1021/jm900095y  0.44
2008 Paul NM, Taylor M, Kumar R, Deschamps JR, Luedtke RR, Newman AH. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol. Journal of Medicinal Chemistry. 51: 6095-109. PMID 18774793 DOI: 10.1021/jm800532x  0.44
2007 Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. Journal of Medicinal Chemistry. 50: 4135-46. PMID 17672446 DOI: 10.1021/jm0704200  0.44
2007 Grundt P, Husband SL, Luedtke RR, Taylor M, Newman AH. Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. Bioorganic & Medicinal Chemistry Letters. 17: 745-9. PMID 17095222 DOI: 10.1016/j.bmcl.2006.10.076  0.44
2007 Corvol JC, Valjent E, Pascoli V, Robin A, Stipanovich A, Luedtke RR, Belluscio L, Girault JA, Hervé D. Quantitative changes in Galphaolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1109-21. PMID 17063155 DOI: 10.1038/sj.npp.1301230  0.44
2006 Vangveravong S, McElveen E, Taylor M, Xu J, Tu Z, Luedtke RR, Mach RH. Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorganic & Medicinal Chemistry. 14: 815-25. PMID 16288878 DOI: 10.1016/j.bmc.2005.09.008  0.44
2005 Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Journal of Medicinal Chemistry. 48: 839-48. PMID 15689168 DOI: 10.1021/jm049465g  0.44
2005 Chu W, Tu Z, McElveen E, Xu J, Taylor M, Luedtke RR, Mach RH. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorganic & Medicinal Chemistry. 13: 77-87. PMID 15582454 DOI: 10.1016/j.bmc.2004.09.054  0.44
2004 Chen J, Rusnak M, Luedtke RR, Sidhu A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. The Journal of Biological Chemistry. 279: 39317-30. PMID 15247297 DOI: 10.1074/jbc.M403891200  0.44
2004 Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorganic & Medicinal Chemistry Letters. 14: 195-202. PMID 14684327 DOI: 10.1016/j.bmcl.2003.09.083  0.44
2004 Luedtke RR, Bell-Horner CL, Volk M, Reinecke MG, Dillon GH. Pharmacological survey of medicinal plants for activity at ligand-gated ion channels: Selective interaction with 5-HT3 receptors Pharmaceutical Biology. 42: 73-82. DOI: 10.1080/13880200490505654  0.44
2003 Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A, Chen CK, DiLeone RJ, Schwarz SC, Selley DE, Sim-Selley LJ, Barrot M, Luedtke RR, Self D, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron. 38: 941-52. PMID 12818179 DOI: 10.1016/S0896-6273(03)00321-0  0.44
2003 Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR. N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists Bioorganic and Medicinal Chemistry Letters. 13: 2179-2183. PMID 12798330 DOI: 10.1016/S0960-894X(03)00389-5  0.44
2003 Mach RH, Huang Y, Freeman RA, Wu L, Blair S, Luedtke RR. Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. Bioorganic & Medicinal Chemistry. 11: 225-33. PMID 12470717 DOI: 10.1016/S0968-0896(02)00341-3  0.44
2003 Luedtke RR, Freeman RA, Volk M, Arfan M, Reinecke MG. Pharmacological survey of medicinal plants for activity at dopamine receptor subtypes. II. Screen for binding activity at the D1 and D2 dopamine receptor subtypes Pharmaceutical Biology. 41: 45-58. DOI: 10.1076/phbi.41.1.45.14695  0.44
2002 Luedtke RR, Freeman RA, Martin MW, Bastien JW, Zalles-Asin J, Reinecke MG. Pharmacological survey of medicinal plants for activity at dopamine receptor subtypes. I. Activation of D1-like receptor linked adenylyl cyclase Pharmaceutical Biology. 40: 315-325. DOI: 10.1076/phbi.40.4.315.8463  0.44
2001 Huang Y, Luedtke RR, Freeman RA, Wu L, Mach RH. Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors Bioorganic and Medicinal Chemistry. 9: 3113-3122. PMID 11711286 DOI: 10.1016/S0968-0896(01)00175-4  0.44
2001 Martin MW, Scott AW, Johnston DE, Griffin S, Luedtke RR. Typical antipsychotics exhibit inverse agonist activity at rat dopamine D1-like receptors expressed in Sf9 cells European Journal of Pharmacology. 420: 73-82. PMID 11408027 DOI: 10.1016/S0014-2999(01)00982-7  0.44
2001 Huang Y, Luedtke RR, Freeman RA, Wu L, Mach RH. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands Journal of Medicinal Chemistry. 44: 1815-1826. PMID 11356115 DOI: 10.1021/jm0100077  0.44
2000 Luedtke RR, Freeman RA, Boundy VA, Martin MW, Huang Y, Mach RH. Characterization of 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors Synapse. 38: 438-449. PMID 11044891 DOI: 10.1002/1098-2396(20001215)38:4<438::AID-SYN9>3.0.CO;2-5  0.44
1999 Nader MA, Green KL, Luedtke RR, Mach RH. The effects of benzamide analogues on cocaine self-administration in rhesus monkeys. Psychopharmacology. 147: 143-52. PMID 10591881  0.44
1999 Luedtke RR, Griffin SA, Conroy SS, Jin X, Pinto A, Sesack SR. Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. Journal of Neuroimmunology. 101: 170-87. PMID 10580800 DOI: 10.1016/S0165-5728(99)00142-3  0.44
1999 Hammond PS, Cheney JT, Johnston DE, Ehrenkaufer RL, Luedtke RR, Mach RH. Synthesis, in vitro dopamine D2 and D3 receptor binding and quantitative structure-activity studies on substituted 2,3-dimethoxy-N-(1- benzyl-4-piperidinyl)benzamides and related compounds Medicinal Chemistry Research. 9: 35-49.  0.44
1999 Mach RH, Hammond PS, Huang Y, Yang B, Xu Y, Cheney JT, Freeman R, Luedtke RR. Structure-activity relationship studies of N-(9-benzyl)-9- azabicyclo[3.3.1]nonan-3-β-yl benzamide analogues for dopamine D2 and D3 receptors Medicinal Chemistry Research. 9: 355-373.  0.44
1998 Yang B, Johnston DE, Luedtke RR, Hammond PS, Mach RH. Synthesis and in vitro binding of N-alkyl-2,3- dimethoxy[3.3.1]azabicyclononane benzamides at dopamine D2 and D3 receptors Medicinal Chemistry Research. 8: 115-131.  0.44
1996 Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Luedtke RR, Kung MP, Kung HF, Lyons D, Morton TE. Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: in vitro binding studies and positron emission tomography. Synapse (New York, N.Y.). 24: 322-33. PMID 10638823 DOI: 10.1002/(SICI)1098-2396(199612)24:4<322::AID-SYN2>3.0.CO;2-F  0.44
1996 Ward AS, Li DH, Luedtke RR, Emmett-Oglesby MW. Variations in cocaine self-administration by inbred rat strains under a progressive-ratio schedule. Psychopharmacology. 127: 204-12. PMID 8912398 DOI: 10.1007/s002130050078  0.44
1996 Oglesby MW, Luedtke R, Ward AS. Integration of molecular biological techniques and behavioral pharmacology: Rationale and impact. Commentary on Gold's 'Integration of molecular biological techniques and behavioural pharmacology' Behavioural Pharmacology. 7: 624-627.  0.44
1995 Essman WD, Luedtke RR, McGonigle P, Lucky I. Variations in the behavioral responses to apomorphine in different strains of rats. Behavioural Pharmacology. 6: 4-15. PMID 11224306  0.44
1995 Mach RH, Ehrenkaufer RL, Greenberg JH, Shao L, Morton TE, Evora PH, Nowak PA, Luedtke RR, Cohen D, Reivich M. PET imaging studies of dopamine D2 receptors: comparison of [18F]N-methylspiperone and the benzamide analogues [18F]MABN and [18F]MBP in baboon brain. Synapse (New York, N.Y.). 19: 177-87. PMID 7784958 DOI: 10.1002/syn.890190305  0.44
1995 Scott AW, Griffin SA, Luedtke RR. Genetic polymorphisms at the rat and murine loci coding for dopamine D2-like receptors Molecular Brain Research. 29: 347-357. PMID 7609622 DOI: 10.1016/0169-328X(94)00271-F  0.44
1993 Boundy VA, Luedtke RR, Artymyshyn RP, Filtz TM, Molinoff PB. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides. Molecular Pharmacology. 43: 666-76. PMID 8502224  0.44
1993 Boundy VA, Luedtke RR, Gallitano AL, Smith JE, Filtz TM, Kallen RG, Molinoff PB. Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. The Journal of Pharmacology and Experimental Therapeutics. 264: 1002-11. PMID 8437101  0.44
1993 Mach RH, Elder ST, Morton TE, Nowak PA, Evora PH, Scripko JG, Luedtke RR, Unsworth CD, Filtz T, Rao AV, Molinoff PB, Ehrenkaufer RLE. The use of [18F]4-fluorobenzyl iodide (FBI) in PET radiotracer synthesis: Model alkylation studies and its application in the design of dopamine D1 and D2 receptor-based imaging agents Nuclear Medicine and Biology. 20: 777-794. PMID 8401379 DOI: 10.1016/0969-8051(93)90165-Q  0.44
1993 Mach RH, Luedtke RR, Unsworth CD, Boundy VA, Nowak PA, Scripko JG, Elder ST, Jackson JR, Hoffman PL, Evora PH. 18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography. Journal of Medicinal Chemistry. 36: 3707-20. PMID 8246241  0.44
1993 Boundy VA, Luedtke RR, Molinoff PB. Development of polyclonal anti-D2 dopamine receptor antibodies to fusion proteins: inhibition of D2 receptor-G protein interaction. Journal of Neurochemistry. 60: 2181-91. PMID 8098355  0.44
1992 Mach RH, Jackson JR, Luedtke RR, Ivins KJ, Molinoff PB, Ehrenkaufer RL. Effect of N-alkylation on the affinities of analogues of spiperone for dopamine D2 and serotonin 5-HT2 receptors. Journal of Medicinal Chemistry. 35: 423-30. PMID 1531364  0.44
1992 Artymyshyn RP, Ivins KJ, Monks BR, Luedtke RR, Molinoff PB. Quantitation of isotypes of D2 receptors using solution hybridization. Neurochemistry International. 20: 189S-195S. PMID 1365424 DOI: 10.1016/0197-0186(92)90237-L  0.44
1992 Luedtke RR, Artymyshyn RP, Monks BR, Molinoff PB. Comparison of the expression, transcription and genomic organization of D2 dopamine receptors in outbred and inbred strains of rat. Brain Research. 584: 45-54. PMID 1355393 DOI: 10.1016/0006-8993(92)90876-B  0.44
1991 Ivins KJ, Luedtke RR, Artymyshyn RP, Molinoff PB. Regulation of dopamine D2 receptors in a novel cell line (SUP1). Molecular Pharmacology. 39: 531-9. PMID 1708089  0.44
1990 Luedtke RR, Bush M, Mach RH, Ehrenkaufer RE, Kung HF, Molinoff PB. Antibodies with high affinity for spiroperidol--II. Cross reactivity with iodobenzamide and domperidone. Molecular Immunology. 27: 667-77. PMID 2395438 DOI: 10.1016/0161-5890(90)90010-W  0.44
1989 Schonwetter BS, Luedtke RR, Kung MP, Billings J, Kung HF, Molinoff PB. Characterization of membrane-bound and soluble D2 receptors in canine caudate using [125I]IBZM. The Journal of Pharmacology and Experimental Therapeutics. 250: 110-6. PMID 2526213  0.44
1988 Luedtke RR, Korner M, Neve KA, Molinoff PB. Monoclonal antibodies with high affinity for spiroperidol. Journal of Neurochemistry. 50: 1253-62. PMID 2964511  0.44
1987 Luedtke RR, Molinoff PB. Characterization of binding sites for [3H]spiroperidol. Biochemical Pharmacology. 36: 3255-64. PMID 2959288 DOI: 10.1016/0006-2952(87)90642-3  0.44
1984 Hamel PA, Isenman DE, Klein MH, Luedtke R, Dorrington KJ. Structural basis for the preferential association of autologous immunoglobulin subunits: Role of the J region of the light chain Molecular Immunology. 21: 277-283. PMID 6427603 DOI: 10.1016/0161-5890(84)90098-1  0.44
1982 Luedtke R, Karush F. Antibody interaction with a membrane-bound fluorescent ligand on synthetic lipid vesicles Biochemistry. 21: 5738-5744. PMID 6817781  0.44
1981 Luedtke R, Owen CS, Vanderkooi JM, Karush F. Proximity relationships within the Fc segment of rabbit immunoglobulin G analyzed by resonance energy transfer Biochemistry. 20: 2927-2936. PMID 7248259  0.44
Show low-probability matches.